AUG Therapeutics
AVTX-803 (L-Fucose)
Leukocyte Adhesion Deficiency
Countdown
146days
Phase 3 readout · Nov 30, 2026
What's at stake
Phase 3 trial results for AVTX-803 (L-Fucose) in Leukocyte Adhesion Deficiency are due Nov 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05462587: Phase 3 trial, sponsor AUG Therapeutics, drug AVTX-803 (L-Fucose). Primary completion date 2026-11-30 (estimated).”